4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge (EToF)

A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge (EToF)

Study Description
Brief Summary:
This study is a randomized controlled trial in which hospitalized patients with anemia are randomized to receive transfusion at: a) Hb<9g/dL (liberal transfusion strategy), or b) Hb<7g/dL (restrictive transfusion strategy). We are measuring self-reported fatigability, fatigue, and activity levels at randomization and 7 days post hospital discharge in both trial arms. In a subset of 75 patients in each trial arm (150 total), we will are administering the 6 Minute Walk Test at randomization and 7 days post discharge.

Condition or disease Intervention/treatment Phase
Anemia Red Blood Cell Transfusion Fatigability Fatigue Physical Function Other: Red blood cell transfusion Not Applicable

Detailed Description:

The design of this proposed study is a randomized controlled trial of hospitalized adult general medicine patients with anemia at the University of Chicago (UC). Patients will be randomized to receive transfusion at either a hemoglobin (Hb)<9g/dL (liberal arm) or a Hb<7g/dL (restrictive arm) throughout their hospitalization. Self-reported fatigability, fatigue, and activity levels will be measured in consented patients at randomization and through a follow-up phone call 7 days after hospital discharge. We will also enroll 150 patients to participate in the Six Minute Walk Test85,86 (6MWT) at randomization and in the clinic 7 days after hospital discharge.

This trial will test whether a liberal transfusion strategy is superior to a restrictive transfusion in hospitalized patients with anemia on fatigability levels after hospital discharge. Our primary outcome is self-reported fatigability level 7 days after hospital discharge measured using the Pittsburgh Fatigability Scale (PFS)71. Secondary outcomes include fatigue measured using the Patient Reported Outcome Measurement Information System (PROMIS) Fatigue Aa instrument, and activity measured by the Physical Activity Scale for the Elderly, and 6MWT distance.

Eligible patients for this trial will be recruited from the University of Chicago Medical Center (UCMC) general medicine services using the University of Chicago Hospitalist Project (UCHP) research infrastructure. The eligibility criteria is: 1) hospitalized adult >18 years of age, 2) admitted to the general medicine services at the University of Chicago, 3) any Hb concentration of <9g/dL during their hospitalization. We will exclude patients who: 1) decline blood transfusion, 2) and/or who have a diagnosis of sickle cell anemia, 3) and/or are brain dead or receiving only palliative treatment, 4) and/or are unable to follow-up after discharge. We will not exclude patients who received transfusion prior to randomization. Eligible patients will be identified using the encrypted UCHP research database, which is programmed to extract real time EHR data into the database in order to identify patients potentially eligible for participation in research studies. The PI and Study Coordinator (SC) will be responsible for patient recruitment and consent.

Consenting patients will be randomized to either receive transfusion when their Hb drops below 7g/dL (restrictive arm) or 9g/dl (liberal arm) at any point during hospitalization, and randomized assignment will be done using permuted block design with random blocks of 2, 4, or 6 patients per block. All red blood cell (RBC) transfusions will be administered in 1 unit increments in order to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, In the case of life-threatening bleeding clinicians will be free to transfuse patients without first checking a patient's Hb concentration. Once randomized, patient's will be managed according to protocol until hospital discharge independent of transfusion to another service and/or specialized hospital ward. This trial will not control or dictate transfusion of other blood products, which will be administered at the discretion of the attending physician caring for the patient.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 748 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomization will occur after patients have consented to participate and will be done using permuted block de-sign with random blocks of 2, 4, or 6 patients per block.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial Comparing a Liberal Versus Restrictive Red Blood Cell Transfusion Strategy on Fatigability, Fatigue, and Activity Levels After Discharge in Hospitalized Patients With Anemia.
Estimated Study Start Date : November 2021
Estimated Primary Completion Date : July 2025
Estimated Study Completion Date : July 2026
Arms and Interventions
Arm Intervention/treatment
Active Comparator: Liberal Transfusion Arm
Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb>9g/dL, and this will be maintained throughout their hospitalization.
Other: Red blood cell transfusion
All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.

Active Comparator: Restrictive Transfusion Arm
Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.
Other: Red blood cell transfusion
All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.

Outcome Measures
Primary Outcome Measures :
  1. Change in self-reported fatigability level [ Time Frame: Fatigability will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
    Self-reported fatigability will be measured by the Pittsburgh Fatigability Scale (PFS). The PFS is a 10 item scale that ranges from 0-50 with greater scores indicating greater fatigability.


Secondary Outcome Measures :
  1. Change in self-reported fatigue level [ Time Frame: Fatigue will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
    Self-reported fatigue will be measured by the Patient-Reported Outcome Measurement Information System (PROMIS-F) Fatigue 8a instrument.The PROMIS-F scores range from 8-40, with higher scores indicating greater fatigue.

  2. Change in self-reported activity level [ Time Frame: Activity will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
    Self-reported activity will be measure by the Physical Activity Scale for the Elderly (PASE). Higher scores on the PASE indicated greater physical activity.

  3. Change in 6 Minute Walk Test (6MWT) distance [ Time Frame: 6MWT will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
    6MWT is measure of functional capacity


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Hospitalized on a general medicine service at the University of Chicago
  • Any hemoglobin (Hb) concentration <9g/dL

Exclusion Criteria:

  • Have sickle cell anemia
  • Decline blood transfusion
  • Are receiving palliative care treatment only
  • Are brain dead
  • Cannot follow up after hospital discharge
Contacts and Locations

Locations
Layout table for location information
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
Contact: Micah T Prochaska, MD, MSc         
Principal Investigator: Micah T Prochaska, MD, MSc         
Sub-Investigator: David O Meltzer, MD, PhD         
Sponsors and Collaborators
University of Chicago
Tracking Information
First Submitted Date  ICMJE May 24, 2021
First Posted Date  ICMJE June 9, 2021
Last Update Posted Date September 30, 2021
Estimated Study Start Date  ICMJE November 2021
Estimated Primary Completion Date July 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 8, 2021)
Change in self-reported fatigability level [ Time Frame: Fatigability will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
Self-reported fatigability will be measured by the Pittsburgh Fatigability Scale (PFS). The PFS is a 10 item scale that ranges from 0-50 with greater scores indicating greater fatigability.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 8, 2021)
  • Change in self-reported fatigue level [ Time Frame: Fatigue will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
    Self-reported fatigue will be measured by the Patient-Reported Outcome Measurement Information System (PROMIS-F) Fatigue 8a instrument.The PROMIS-F scores range from 8-40, with higher scores indicating greater fatigue.
  • Change in self-reported activity level [ Time Frame: Activity will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
    Self-reported activity will be measure by the Physical Activity Scale for the Elderly (PASE). Higher scores on the PASE indicated greater physical activity.
  • Change in 6 Minute Walk Test (6MWT) distance [ Time Frame: 6MWT will be measured at admission to the hospital during the index hospitalization and 7 days after hospital discharge. ]
    6MWT is measure of functional capacity
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge
Official Title  ICMJE A Trial Comparing a Liberal Versus Restrictive Red Blood Cell Transfusion Strategy on Fatigability, Fatigue, and Activity Levels After Discharge in Hospitalized Patients With Anemia.
Brief Summary This study is a randomized controlled trial in which hospitalized patients with anemia are randomized to receive transfusion at: a) Hb<9g/dL (liberal transfusion strategy), or b) Hb<7g/dL (restrictive transfusion strategy). We are measuring self-reported fatigability, fatigue, and activity levels at randomization and 7 days post hospital discharge in both trial arms. In a subset of 75 patients in each trial arm (150 total), we will are administering the 6 Minute Walk Test at randomization and 7 days post discharge.
Detailed Description

The design of this proposed study is a randomized controlled trial of hospitalized adult general medicine patients with anemia at the University of Chicago (UC). Patients will be randomized to receive transfusion at either a hemoglobin (Hb)<9g/dL (liberal arm) or a Hb<7g/dL (restrictive arm) throughout their hospitalization. Self-reported fatigability, fatigue, and activity levels will be measured in consented patients at randomization and through a follow-up phone call 7 days after hospital discharge. We will also enroll 150 patients to participate in the Six Minute Walk Test85,86 (6MWT) at randomization and in the clinic 7 days after hospital discharge.

This trial will test whether a liberal transfusion strategy is superior to a restrictive transfusion in hospitalized patients with anemia on fatigability levels after hospital discharge. Our primary outcome is self-reported fatigability level 7 days after hospital discharge measured using the Pittsburgh Fatigability Scale (PFS)71. Secondary outcomes include fatigue measured using the Patient Reported Outcome Measurement Information System (PROMIS) Fatigue Aa instrument, and activity measured by the Physical Activity Scale for the Elderly, and 6MWT distance.

Eligible patients for this trial will be recruited from the University of Chicago Medical Center (UCMC) general medicine services using the University of Chicago Hospitalist Project (UCHP) research infrastructure. The eligibility criteria is: 1) hospitalized adult >18 years of age, 2) admitted to the general medicine services at the University of Chicago, 3) any Hb concentration of <9g/dL during their hospitalization. We will exclude patients who: 1) decline blood transfusion, 2) and/or who have a diagnosis of sickle cell anemia, 3) and/or are brain dead or receiving only palliative treatment, 4) and/or are unable to follow-up after discharge. We will not exclude patients who received transfusion prior to randomization. Eligible patients will be identified using the encrypted UCHP research database, which is programmed to extract real time EHR data into the database in order to identify patients potentially eligible for participation in research studies. The PI and Study Coordinator (SC) will be responsible for patient recruitment and consent.

Consenting patients will be randomized to either receive transfusion when their Hb drops below 7g/dL (restrictive arm) or 9g/dl (liberal arm) at any point during hospitalization, and randomized assignment will be done using permuted block design with random blocks of 2, 4, or 6 patients per block. All red blood cell (RBC) transfusions will be administered in 1 unit increments in order to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, In the case of life-threatening bleeding clinicians will be free to transfuse patients without first checking a patient's Hb concentration. Once randomized, patient's will be managed according to protocol until hospital discharge independent of transfusion to another service and/or specialized hospital ward. This trial will not control or dictate transfusion of other blood products, which will be administered at the discretion of the attending physician caring for the patient.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Randomization will occur after patients have consented to participate and will be done using permuted block de-sign with random blocks of 2, 4, or 6 patients per block.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Anemia
  • Red Blood Cell Transfusion
  • Fatigability
  • Fatigue
  • Physical Function
Intervention  ICMJE Other: Red blood cell transfusion
All RBC transfusions will be administered in 1 unit increments to maintain patients' Hb concentration above the trial arm threshold they are randomized to. All transfusions will be followed by a Hb measure and an additional unit(s) of RBC's will only be transfused if there is documentation of the patient's Hb concentration below the trial arm threshold they are randomized to. However, in the case of life-threatening bleeding clinicians will be able to transfuse patients without first checking a patient's Hb concentration. Once randomized, patients will be man-aged according to protocol until hospital discharge independent of transfer to another service and/or specialized hospital ward.
Study Arms  ICMJE
  • Active Comparator: Liberal Transfusion Arm
    Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb>9g/dL, and this will be maintained throughout their hospitalization.
    Intervention: Other: Red blood cell transfusion
  • Active Comparator: Restrictive Transfusion Arm
    Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.
    Intervention: Other: Red blood cell transfusion
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: June 8, 2021)
748
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2026
Estimated Primary Completion Date July 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥ 18 years
  • Hospitalized on a general medicine service at the University of Chicago
  • Any hemoglobin (Hb) concentration <9g/dL

Exclusion Criteria:

  • Have sickle cell anemia
  • Decline blood transfusion
  • Are receiving palliative care treatment only
  • Are brain dead
  • Cannot follow up after hospital discharge
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04920045
Other Study ID Numbers  ICMJE IRB21-0854
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Micah Prochaska, University of Chicago
Study Sponsor  ICMJE University of Chicago
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account University of Chicago
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP